Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT02161731
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 62
- Registration Number
- NCT02156492
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT02154646
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT02152371
- Locations
- 🇺🇸
Valley Endocrine, Fresno, Fresno, California, United States
🇺🇸Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States
🇺🇸Mills-Peninsula Diabetes Research Insitute, San Mateo, California, United States
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT02152384
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 453
- Registration Number
- NCT02152631
- Locations
- 🇺🇸
St Joseph Cancer Center, Englewood, Colorado, United States
🇧🇷Hospital Bruno Born, Lajeados, Brazil
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
Safety Study of LY3041658 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY3041658 (IV)Drug: LY3041658 (SC)Drug: Placebo
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 54
- Registration Number
- NCT02148627
- Locations
- 🇺🇸
Parexel Early Phase Unit at Glendale, Glendale, California, United States
🇺🇸PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore, Maryland, United States
A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis
- Conditions
- Kidney Failure, Chronic
- Interventions
- Drug: PlaceboDrug: LY3113593
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 64
- Registration Number
- NCT02144285
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Parexel Early Phase Unit at Glendale, Glendale, California, United States
Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis
- Conditions
- Inflammatory Arthritis
- Interventions
- Drug: PlaceboDrug: LY3114062 SCDrug: LY3114062 IV
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2015-07-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 41
- Registration Number
- NCT02144272
- Locations
- 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania
A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT02132637
- Locations
- 🇺🇸
Profil Institute for Clinical Research Inc, Chula Vista, California, United States
🇩🇪For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany